Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
E H EsteyS Kornblau

Abstract

To determine whether granulocyte colony-stimulating factor (G-CSF) administered before, during, and after fludarabine plus cytarabine (ara-C; FA) chemotherapy affected complete response (CR) rate, infection rate, blood count recovery, or survival in patients with newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). A total of 112 patients with newly diagnosed AML (n = 69) or MDS (n = 43) received G-CSF 400 micrograms/m2/d 1 day before (presenting WBC count < 50,000/microL) and/or during (all patients) fludarabine 30 mg/m2/d and ara-C 2 g/m2/d for 5 days (FLAG). G-CSF continued until a CR was achieved. Results were compared with those in 85 newly diagnosed patients (54 AML, 31 MDS) previously treated with FA without G-CSF. Patients in both groups were relatively old (median age of all patients, 63 years), and were likely to have prognostically unfavorable cytogenetic abnormalities (36% had abnormalities of chromosomes 5 and 7 [-5/-7]). G-CSF accelerated recovery to > or = 1,000 neutrophils (P < .0001; median, 34 days for FA, 21 days for FLAG), but logistic regression provided no evidence that the CR rate was higher with FLAG than with FA (P = .50), with unadjusted CR rates of 63% and 53%, respecti...Continue Reading

Citations

Sep 1, 1995·British Journal of Haematology·A TafuriF Mandelli
Jun 13, 1998·American Journal of Hematology·M MontilloF Ferrara
May 7, 1998·Leukemia & Lymphoma·A Ganser, M Karthaus
Apr 29, 2000·Current Opinion in Hematology·J M Rowe
Feb 22, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Q NguyenE Whimbey
Jan 9, 2003·Expert Opinion on Biological Therapy·Fenella Willis, Ruth Pettengell
Apr 12, 2003·Leukemia & Lymphoma·Tadeusz Robak
Oct 24, 2006·British Journal of Haematology·UNKNOWN British Committee for Standards in HaematologyG Jackson
Feb 25, 2009·Expert Opinion on Pharmacotherapy·Michael J Absalon, Franklin O Smith
Mar 8, 2012·Journal of Pediatric Hematology/oncology·Paola QuarelloFranca Fagioli
Jan 10, 2012·Leukemia & Lymphoma·Shaun FlemingJohn F Seymour
Sep 13, 2012·British Journal of Haematology·Jeffrey E Rubnitz, Hiroto Inaba
Oct 23, 2013·Annals of Hematology·Marcela Deffis-CourtErick Crespo-Solís
May 29, 2018·Cancer·Martha Arellano, Jennifer Wilkinson Carlisle
Nov 26, 1999·Cancer·H D Preisler
Jun 27, 2000·Australian and New Zealand Journal of Medicine·A H StricklandE H Januszewicz
Nov 26, 2002·Hematology·Francis J GilesHagop M Kantarjian
Sep 5, 2002·Drugs & Aging·Graham H Jackson, Penelope R A Taylor

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.